Clinical Trials Logo

Filter by:
NCT ID: NCT02392273 Terminated - Clinical trials for Primary Headache Disorders

A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil

Start date: February 2015
Phase: N/A
Study type: Observational

This study is an observational study with the primary objective to assess the safety and tolerability of Ausanil in the treatment of primary headache disorders. The secondary objective is to assess headache pain, functional outcome, time loss to headache and patient satisfaction with Ausanil treatment.

NCT ID: NCT02392156 Terminated - Hemophilia A Clinical Trials

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

FORWARD
Start date: July 2015
Phase:
Study type: Observational

The primary objective of the study is to evaluate the effectiveness of prophylactic treatment with recombinant Factor VIII Fc fusion protein (rFVIIIFc) and recombinant Factor IX Fc fusion protein (rFIXFc) therapy as assessed by patient treatment burden and health economic outcomes while maintaining disease control in males with hemophilia A or B.

NCT ID: NCT02392039 Terminated - Lymphoma Clinical Trials

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Start date: December 14, 2015
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical research study is to learn if loratadine can control bone pain caused by pegfilgrastim (a drug given after chemotherapy to help raise white blood cell counts).

NCT ID: NCT02391545 Terminated - Clinical trials for CD20+ Follicular Lymphoma

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.

NCT ID: NCT02390401 Terminated - Clinical trials for Surgical Wound Infection

Vacuum Assisted Closure for Cesarean Section

VACCS
Start date: May 2015
Phase: Phase 1
Study type: Interventional

To study if incisional vacuum-assisted closure can decrease the risk of infection in cesarean section incisions in the obese compared with standard sterile dressing.

NCT ID: NCT02390362 Terminated - Clinical trials for Steroid Dependent Nephrotic Syndrome

Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome

RAMP
Start date: January 2015
Phase: Phase 3
Study type: Interventional

We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children with frequent relapsing or steroid dependent nephrotic syndrome who have had one relapse while receiving MMF. We will conduct a randomized study comparing two Rituximab infusions and continued MMF treatment. We plan to enroll 64 to have a comparater group of 58 (29 in each arm).

NCT ID: NCT02389985 Terminated - Ovarian Cancer Clinical Trials

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Start date: July 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer. Determine through pharmacokinetic evaluation(sometimes described as what the body does to a drug, refers to the movement of drug into, through and out of the body-the time and course of its absorption, bioavailability, distribution, metabolism, and excretion) whether or not the disposition of paclitaxel is affected by the concurrent administration of CRLX101.

NCT ID: NCT02389764 Terminated - Breast Cancer Clinical Trials

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Start date: June 22, 2015
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied. This is an investigational study. Nintedanib is commercially available and FDA approved for the treatment of certain types of lung disease. Its use in this study is investigational. The study doctor can explain how the study drug is designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT02389712 Terminated - Bipolar Disorder Clinical Trials

16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression

FLAME
Start date: March 2015
Phase: Phase 4
Study type: Interventional

The FLAME Study is a 16-week clinical trial to study treatment with lamotrigine or fluoxetine in bipolar I, II and bipolar schizoaffective depressed adults. The purpose of the trial is to have a better understanding of whether individuals with a particular gene type and other inherited biological markers will have a good response to fluoxetine or lamotrigine, or alternatively, would be more likely to have side effects to this medication.

NCT ID: NCT02388932 Terminated - Clinical trials for Recurrent Laryngeal Squamous Cell Carcinoma

Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer

Start date: March 3, 2015
Phase: N/A
Study type: Interventional

This phase I trial studies the side effects and best dose of stereotactic body radiation therapy (SBRT) in treating participants with head and neck cancer that has spread from where it started to nearby tissue or lymph nodes and is at high risk for continuing to spread because the participant cannot undergo standard chemotherapy. Stereotactic body radiation therapy is a specialized radiation therapy that delivers radiation directly to the tumor in smaller doses over several days, which may kill more tumor cells and cause less damage to normal tissue.